PMDA drug package insert
タゾピペ配合静注用2.25「明治」
PMDA Prescription drug · Meiji Seika ファルマ株式会社 · package insert Sep 26, 2023
Key facts
| Brand names | タゾピペ配合静注用2.25「明治」, タゾピペ配合静注用4.5「明治」 |
|---|---|
| Nonproprietary names | タゾバクタム・ピペラシリン水和物 |
| Companies | 製造販売元／Meiji Seika ファルマ株式会社 |
| Product type | Prescription drug |
| Therapeutic category | β-ラクタマーゼ阻害剤配合抗生物質製剤 |
| Therapeutic category codes | 876139 |
| YJ codes | 6139505F3127, 6139505F4123 |
| Approval numbers | 22700AMX00928000, 22700AMX00929000 |
| Package insert edition | 第2版 |
| Package insert date | Sep 26, 2023 |
| PMDA document key | 780009_6139505F3127_1 |
| PMDA company code | 780009 |
At a glance
- 1–9 Package insert revisions
- 10–99 Related PMDA documents
- None Safety communications
- No PMDA review report published
- No Risk management plan (RMP)
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMDA approved drugs and package inserts (Japan)
Japan's PMDA publishes the package insert (添付文書) of every prescription drug, OTC drug and regenerative medical product, with brand and nonproprietary names, YJ codes and approval numbers. Names appear in Japanese as published.
Source: Pharmaceuticals and Medical Devices Agency (PMDA), Japan, package insert database · Source date: